Chimerix Announces Second Quarter 2019 Financial Results and Operational Update

NEXT STORY
Generex Biotechnology Announces Interview with President & CEO Joe Moscato
PREV STORY
Ziopharm Oncology Reports Second Quarter 2019 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease

author_avatar
NASDAQ Market News

Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study

author_avatar
NASDAQ Market News

European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

author_avatar
NASDAQ Market News